COMMENTARY

Commentary on “Experience and challenges for biologic use for the treatment of moderate-to-severe psoriasis in Africa and the Middle East region”


Recently, in the Journal of Dermatological Treatment, Al Hammadi published an article discussing the authors' experiences, as well as some challenges faced, when using biologic therapies in patients with moderate-to-severe psoriasis living in Africa and the Middle East (AIME). As Al Hammadi points out, psoriasis has been designated by the World Health Organization (WHO) as a “chronic, non-communicable, painful, disfiguring and disabling disease for which there is no cure” (2); yet awareness of this condition and how best to approach its treatment seems low in AIME.

The burden of psoriasis in the AIME region is not accurately recorded but may be higher and present with more serious features than epidemiology data in western countries suggest. Although biologic therapies for the treatment of psoriasis have been available in AIME countries for over a decade, data on their actual use are lacking, and it is believed that local experience with these therapeutic agents is scarce. This is particularly worrisome when it is remembered that use of biologics has been associated with an increased risk of developing not only psoriatic arthritis (PsA) and inflammatory bowel disease (IBD) but also certain cancers, cardiovascular diseases including heart attack and stroke, diabetes or metabolic syndrome, obesity and depression (3), all of which are also certain cancers, cardiovascular diseases including heart attack and stroke, diabetes or metabolic syndrome, obesity and depression (3), all of which are already believed highly prevalent in AIME. It is well known that moderate-to-severe psoriasis responds well to biologic therapy in many patients, but to-severe psoriasis living in Africa and the Middle East (AIME). As Al Hammadi points out, psoriasis has been designated by the World Health Organization (WHO) as a “chronic, non-communicable, painful, disfiguring and disabling disease for which there is no cure” (2); yet awareness of this condition and how best to approach its treatment seems low in AIME.

The burden of psoriasis in the AIME region is not accurately recorded but may be higher and present with more serious features than epidemiology data in western countries suggest. Although biologic therapies for the treatment of psoriasis have been available in AIME countries for over a decade, data on their actual use are lacking, and it is believed that local experience with these therapeutic agents is scarce. This is particularly worrisome when it is remembered that use of biologics has been associated with an increased risk of developing not only psoriatic arthritis (PsA) and inflammatory bowel disease (IBD) but also certain cancers, cardiovascular diseases including heart attack and stroke, diabetes or metabolic syndrome, obesity and depression (3), all of which are already believed highly prevalent in AIME. It is well known that moderate-to-severe psoriasis responds well to biologic therapy in many patients, but to-severe psoriasis living in Africa and the Middle East (AIME). As Al Hammadi points out, psoriasis has been designated by the World Health Organization (WHO) as a “chronic, non-communicable, painful, disfiguring and disabling disease for which there is no cure” (2); yet awareness of this condition and how best to approach its treatment seems low in AIME.

National or local guidelines for the treatment of psoriasis in AIME countries are glaringly lacking, with only Saudi Arabia and South Africa producing their own. Most clinicians in the region rely on US or European recommendations to inform treatment decision making—but these international guidelines do not take into account local medical, legal, religious or practical considerations relevant for AIME. Hurdles to providing adequate treatment for psoriasis patients in AIME countries are manifold. There is an urgent need for AIME-specific guidelines as well as screening programmes, standardized methodologies and availability of technology to detect anti-biologic drug use (AIDU) formation, disease registries and patient associations and support groups. Also, clinical trials conducted in AIME patients with psoriasis would provide useful information on how different ethnic groups, which are typically underrepresented in clinical trials conducted in western countries, respond to treatments.

Local guidelines for the treatment of psoriasis and PsA specifically in the AIME region are clearly required. New screening tools for comorbidities are also needed to optimize the management of psoriasis. Physicians should be aware of the problem of non-adherence to systemic treatment in chronic diseases; drivers of non-adherence should be identified and tailored solutions adopted to improve the level of adherence. Likewise, a patient-centred approach to psoriasis care may help optimize outcomes and reduce the physical, social and economic burden of psoriasis and PsA in the AIME region.

In conclusion, psoriasis affects people in AIME at least as harshly as elsewhere in the world, and possibly more so. This chronic condition is a known risk factor for developing an array of other serious diseases and has its own hazard for an increased mortality (4). Psoriasis also profoundly influences patients’ loss of work productivity. All these factors present an immense strain in an area of the world where there are already many social and economic problems. Biologic therapies have been definitively demonstrated to improve psoriasis symptomatology and are available in AIME. Reported experiences of clinicians working with psoriasis patients in AIME countries have been so far encouraging. The challenge from now is how to build on these foundations, improve awareness of psoriasis and expand access to biologics and other effective therapies against moderate-to-severe forms of this disease in the AIME region.

REFERENCES